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Issues in Group Sequential/Adaptive Designs
Abstract
In recent years, there has been great interest in the use of adaptive features in clinical trials (i.e., changes in
design or analyses guided by examination of the accumulated data at an interim point in the trial) that may
make the studies more efficient (e.g., shorter duration, fewer patients). Many statistical methods have been
developed to maintain the validity of study results when adaptive designs are used (e.g., control of the Type I
error rate). Group sequential designs, which allow early stopping for efficacy in light of compelling evidence of
benefit or early stopping for futility when the likelihood of success is low at interim analyses, have been widely
used for many years. In this dissertation, we study several aspects of statistical issues in group sequential/
adaptive designs. Sample size re-estimation has drawn a great deal of interest due to its permitting revision of
the target treatment difference based on the unblinded interim analysis results from an ongoing trial. A
possible risk of ublinded sample size re-estimation is that the exact treatment effect being observed at interim
analysis might be back-calculated from the modified sample size, which might jeopardize the integrity of the
trial. In the first project, we propose a pre-specified stepwise two-stage sample size adaptation to lessen the
information on treatment effect that would be revealed. We minimize expected sample size among a class of
these designs and compare efficiency with the fully optimized two-stage design, optimal two-stage group
sequential design and designs based on promising conditional power. In the second project, we define the
complete ordering of a group sequential sample space and show that a Wang-Tsiatis boundary family or an
exponential spending function family can completely order the sample space. We also propose a simple
method to transform a spending function to a completely ordered sample space when using the sequential p-
value ordering. This method is also extended to β-spending functions for p-values to reject the alternative
hypothesis. In the third project, we propose a simple approach for controlling the familywise error rate in a
group sequential design with multiple testing. We apply sequential p-values at the interim analysis from a
group sequential design to the sequentially rejective graphical procedure which is based on the closure
principle. We also use simulations to study the operating characteristics of multiple testing in group sequential
designs. We show that in terms of expected sample size, using a group sequential design in multiple hypothesis
testing is more efficient than fixed sample size designs in many scenarios.
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ABSTRACT
ISSUES IN GROUP SEQUENTIAL/ADAPTIVE DESIGNS
Hong Wan
Susan Ellenberg
In recent years, there has been great interest in the use of adaptive features in
clinical trials (i.e., changes in design or analyses guided by examination of the ac-
cumulated data at an interim point in the trial) that may make the studies more
efficient (e.g., shorter duration, fewer patients). Many statistical methods have been
developed to maintain the validity of study results when adaptive designs are used
(e.g., control of the Type I error rate). Group sequential designs, which allow early
stopping for efficacy in light of compelling evidence of benefit or early stopping for
futility when the likelihood of success is low at interim analyses, have been widely
used for many years. In this dissertation, we study several aspects of statistical is-
sues in group sequential/adaptive designs. Sample size re-estimation has drawn a
great deal of interest due to its permitting revision of the target treatment difference
based on the unblinded interim analysis results from an ongoing trial. A possible
risk of ublinded sample size re-estimation is that the exact treatment effect being
observed at interim analysis might be back-calculated from the modified sample size,
which might jeopardize the integrity of the trial. In the first project, we propose a
pre-specified stepwise two-stage sample size adaptation to lessen the information on
treatment effect that would be revealed. We minimize expected sample size among
iv
a class of these designs and compare efficiency with the fully optimized two-stage
design, optimal two-stage group sequential design and designs based on promising
conditional power. In the second project, we define the complete ordering of a group
sequential sample space and show that a Wang-Tsiatis boundary family or an ex-
ponential spending function family can completely order the sample space. We also
propose a simple method to transform a spending function to a completely ordered
sample space when using the sequential p-value ordering. This method is also ex-
tended to β-spending functions for p-values to reject the alternative hypothesis. In
the third project, we propose a simple approach for controlling the familywise error
rate in a group sequential design with multiple testing. We apply sequential p-values
at the interim analysis from a group sequential design to the sequentially rejective
graphical procedure which is based on the closure principle. We also use simulations
to study the operating characteristics of multiple testing in group sequential designs.
We show that in terms of expected sample size, using a group sequential design in
multiple hypothesis testing is more efficient than fixed sample size designs in many
scenarios.
v
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Chapter 1
Introduction
Clinical trials often take long time and a lot of resources to conduct. Interim anal-
yses are often performed in clinical trials because of ethical and economical reasons.
There is an ethical need to ensure that patients are not exposed to unsafe, inferior
or ineffective treatments. Early stopping may also allow highly effective medicines to
come to market faster for patients who do not have good treatment options. Early
completion can also free up resources for studies addressing other pressing medical
issues.
In recent years, the potential use of adaptive designs in clinical trials have attracted
great interest because of the potential gain of efficiency in drug development processes
(e.g., shorter duration, fewer patients). The Pharmaceutical Research and Manufac-
turers of America (PhRMA) has formed an adaptive design working group to promote
the usage of adaptive designs and related methodology (Gallo et al. (2006)). The Eu-
ropean Medicines Agency (EMA) published a “Reflection paper on methodological
1
issues in confirmatory clinical trials planned with an adaptive design” (EMA (2007)).
The Food and Drug Administration (FDA) recently released the draft guidance on
adaptive design clinical trials and discussed various aspects of usage, considerations,
challenges of application of adaptive design trials (Food and Drug Administration
(2010)). The FDA draft guidance defines an adaptive design clinical study as “a
study that includes a prospectively planned opportunity for modification of one or
more specified aspects of the study design and hypotheses based on analysis of data
(usually interim data) from subjects in the study.” Various aspects of clinical trials
could be modified at interim analysis; these include, but are not limited to, study dose,
treatment duration, study endpoints, randomization, study design, study hypotheses,
sample size, etc.
Sample size re-estimation based on unblinded interim effect size estimates has
drawn a great deal of interest due to its permitting revision of the hypothesized treat-
ment difference from an ongoing trial while preserving the Type I error rate. When
there is uncertainty about the assumptions of treatment effect at the design stage, it
would be valuable to check these assumptions and make a midcourse adjustment to
maintain the study power. Several adaptive design methods have been proposed to
re-estimate sample size using the observed treatment effect after an initial stage of a
clinical trial while preserving the overall Type I error at the time of the final analy-
sis (Proschan and Hunsberger (1995); Cui et al. (1999); Mu¨ller and Scha¨ffer (2001)).
One unfortunate property of the algorithms used in some methods is that they can be
2
inverted to reveal the exact treatment effect at the interim analysis (Ellenberg et al.
(2006)). In Chapter 2, we propose using a step function with an inverted U-shape of
observed treatment difference for sample size re-estimation to lessen the information
on treatment effect revealed. This will be referred to as stepwise two-stage sample
size adaptation. This method applies calculation methods used for group sequential
designs. We minimize expected sample size among a class of these designs and com-
pare efficiency with the fully optimized two-stage design, optimal two-stage group
sequential design and designs based on promising conditional power. The tradeoff
between efficiency versus the improved blinding of the interim treatment effect is also
discussed.
Armitage, McPherson, and Rowe (1969) had numerically shown that repeated
testing at a fixed level at interim analyses inflates the overall Type I error rate. Group
sequential designs (Pocock (1977); O’Brien and Fleming (1979); Lan and DeMets
(1983); Jennison and Turnbull (2000); etc.) have been developed and are well accepted
to control the Type I error rate with possible early stopping to either accept or reject
the null hypothesis. P-values are often used to measure the strength of evidence
against the null hypothesis in favor of the alternative. An ordered outcome space
is required to compute a p-value. Unlike a fixed sample design, a group sequential
trial might stop early and the densities for the group sequential statistics used to
stop the trial lack a monotone likelihood ratio. There are several ways to order the
sample space for a group sequential design, e.g., stage-wise ordering by Tsiatis, Rosner
3
and Mehta (1984); maximum likelihood estimate (MLE) ordering by Emerson and
Fleming (1990); likelihood ratio ordering or z-score ordering by Chang (1989); score
test ordering or B-value ordering by Rosner and Tsiatis (1988); and sequential p-value
ordering by Liu and Anderson (2008a). In Chapter 3, we review the existing sample
space orderings for group sequential designs and we show the advantage of sequential
p-value ordering because this method uses the totality of the accumulating data,
taking into account the entire sample path, while the other orderings only consider
the data where the boundary was crossed or the data at the current analysis. We
show that some spending functions could not completely order the sample space
when sequential p-value ordering is used to test the null hypothesis (Type I error).
We propose a simple method to transform such a spending function to one which
can completely order a group sequential design sample space. We also extend the
sequential p-value ordering to test the alternative hypothesis (Type II error). The
two one-sided sequential p-values against the null or alternative hypothesis may be
useful for a Data Monitoring Committee (DMC) making an appropriate decision.
Much of the work on group sequential methods was developed under a single end-
point. Clinical trials often involve more than one endpoint. It is of interest to extend
the group sequential methods in the multiple endpoint/testing context. Less litera-
ture is available for this topic. In Chapter 4, we propose to apply sequential p-values
methods to closed test based multiple testing procedures to control the familywise
error rate for a group sequential design with multiple testing. We run simulations to
4
study power and expected sample size of a group sequential design with two primary
and two secondary endpoints. We study the operating characteristics of this design
under many different scenarios of design parameters and using different spending
functions for secondary endpoints.
5
Chapter 2
Stepwise two-stage sample size
adaptation
2.1 Introduction
Different adaptive design methods have been proposed to modify sample size based
on unblinded results from interim analysis while preserving the Type I error rate.
Proschan and Hunsberger (1995) proposed a two-stage adaptive design to re-estimate
second-stage sample size based on conditional power assuming the observed interim
treatment effect. Liu and Chi (2001) varied this approach based on conditional power
computed under the minimum treatment effect of interest. Anderson and Liu (2004)
showed that the latter approach improves efficiency compared to the former approach.
Cui et al. (1999) preserved the overall Type I error by combining the Wald statistics
with pre-specified weights, obtained before and after sample size adaptation. Mu¨ller
6
and Scha¨ffer (2001) showed the overall Type I error can be preserved unconditionally
under any general adaptive change given that the conditional Type I error is preserved.
Posch et al. (2003) investigated an ‘optimal’ reassessment rule which minimizes the
expected sample size over some set of fixed alternatives with an overall desired power
at the minimum treatment effect of interest. They described the optimal second-stage
sample size as a polynomial function of the first-stage test statistic given the stopping
boundaries and preplanned weights of the group sequential designs. Lokhnygina and
Tsiatis (2008) proposed a fully optimized, decision-theoretic two-stage adaptive group
sequential design to achieve the minimum expected sample size averaged over a normal
prior or some fixed alternatives for the treatment effect. This optimal two-stage design
is adaptive in that the sample size at the second stage depends on the data from the
first stage. They used backward induction algorithm to solve for a Bayesian sequential
decision problem following Schmitz (1993), and Barber and Jennison (2002).
The re-estimated sample size in the second stage from these adaptive designs is a
continuous function of the observed test statistic (treatment effect) at the first interim
analysis. Given the study design and the second-stage sample size, the treatment
effect at the interim analysis might be back-calculated. This is generally considered
a poor feature of these designs (Ellenberg et al. (2006)). One way to reduce the
information revealed about the treatment effect in the interim analysis is to make the
second-stage sample size a step function of interim treatment effect, i.e., to provide
a few sample size choices given the interim test results.
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In this paper, we outline a pre-specified two-stage design with a limited set of
stage two sample size possibilities and minimizing the expected sample size under
the assumption of a normal prior for the treatment effect. We compare this design
with the fully optimized two-stage adaptive design (Lokhnygina and Tsiatis (2008)),
optimal two-stage group sequential designs (Anderson (2007)) and designs based on
promising conditional power (Gao et al. (2008), Mehta and Pocock (2011)). We
conclude with a discussion in the final section.
2.2 A two-stage design with a limited set of stage
two sample size possibilities
Assume X1, X2, . . . are independent and identically distributed with a Normal
(θ,1) distribution. Let θ represent the single parameter of interest, which is the
treatment effect in our case. Assume n1 is the first-stage sample size and there are
m−1 possible stage two sample sizes at the first interim analysis. For i = 1, 2, . . . ,m,
ni is a sequence of positive integers and denote
Zi =
ni∑
j=1
Xi/
√
ni.
We will assume n1 < ni, i = 2, 3, . . . ,m, but that otherwise these numbers are not
ordered in any particular way. The amount of statistical information about θ after
ni observations and will be denoted by Ii, i = 1, 2, . . . ,m. Under these assumptions
the statistics Zi, i = 1, 2, 3, . . . ,m, have a multivariate normal distribution where if
8
1 ≤ nj ≤ ni we have
E{Zi} = θ
√
Ii, (2.2.1)
Cov(Zj, Zi) =
√
Ij/Ii (2.2.2)
Jennison and Turnbull (2000) refer to this as the ‘canonical form’ when used with
group sequential designs where n1 < n2 < . . . < nm. It is the asymptotic form for
a broad variety of group sequential designs with endpoints having different distribu-
tions.
We consider two-stage designs both since the two-stage design should be simple
to implement and because it minimizes what is revealed about the interim treatment
effect. For some initial sample size n1 we compute a test statistic Z1 and for some
integer m > 1 we consider boundary values a1 < a2 < . . . < am. The trial is stopped
after the analysis of n1 patients for a positive efficacy finding if Z1 ≥ am, while if
Z1 < a1 the trial is stopped for futility. For i = 2, 3, . . . ,m, if ai−1 ≤ Z1 < ai the
trial continues to the second stage with a sample size of ni > n1, a test statistic Zi is
computed based on the mean of the entire ni observations, and for some real value bi
efficacy is established if Zi > bi. In this two-stage design setting, b1 = am. Note that
for i = 2, 3, . . . ,m there is no restriction on the ordering of the ni values. If they are
all equal or if m = 2, this becomes a two-stage group sequential design.
The probability of crossing an upper bound at the first interim analysis with n1
observations is
α1(θ) = Pθ{Z1 ≥ am} (2.2.3)
9
For i = 2, 3, . . . ,m the probability of the first interim test statistic being between ai−1
and ai and then crossing the upper bound after ni observations at the second stage is
αi(θ) = Pθ{{ai−1 ≤ Z1 < ai} ∩ {Zi ≥ bi}}. (2.2.4)
Similarly, the probability of crossing a lower bound at the first interim analysis
with n1 observations is
β1(θ) = Pθ{Z1 < a1} (2.2.5)
For i = 2, 3, . . . ,m the probability of the first interim test statistic being between ai−1
and ai and then failing to cross the upper boundary at the second stage after ni > n1
observations is
βi(θ) = Pθ{{ai−1 ≤ Z1 < ai} ∩ {Zi < bi}}. (2.2.6)
These probabilities can be computed using group sequential design computations
as outlined in Jennison and Turnbull (2000). The total probability of crossing an
upper bound at any time is
α(θ) =
m∑
i=1
αi(θ) (2.2.7)
and the Type I error for the design is α(0). The probability of being below a lower
boundary (a1 for the first interim analysis and bi for stage two analysis after ni patients
for i = 2, 3, . . . ,m) is
β(θ) =
m∑
i=1
βi(θ) (2.2.8)
For any given θ,
α(θ) + β(θ) = 1 (2.2.9)
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2.3 Reparameterizing the design
The design can be parameterized by using the sample sizes and boundaries, e.g.,
ni, ai and bi, for i = 1, 2, . . . ,m. Our goal is to achieve the minimum expected sample
size over a range of alternatives. We will reparameterize the design here, beginning
with boundary crossing probabilities under the null hypothesis and relative sample
sizes at the different stages of the design.
The overall Type I error for the design is
α ≡ α(0) =
m∑
i=1
αi(0) (2.3.1)
The probability of a negative finding under the null hypothesis is
1− α = β(0) =
m∑
i=1
βi(0) (2.3.2)
Leaving ni fixed for i = 1, 2, . . . ,m we can map back and forth from a parame-
terization using a1 and ai, bi, i = 2, 3, . . . ,m, to another using α and αi(0), βi(0),
i = 2, 3, . . . ,m. We briefly discuss the method for doing this. First, consider the
bounds at the first stage. Since β1(0) = P{Z1 < a1} we have a1 = Φ−1(β1(0)) where
Φ−1() represents the inverse of the standard normal cumulative distribution function.
Next, note that for i = 2, . . . ,m
P0{Zi < ai} = Φ(ai) = β1(0) +
i∑
j=2
(αj(0) + βj(0)) (2.3.3)
and thus
ai = Φ
−1
(
β1(0) +
i∑
j=2
(αj(0) + βj(0))
)
. (2.3.4)
11
For i = 2, 3, . . . ,m the value of bi is a solution to the equation
βi(0) = P0{{ai−1 ≤ Z1 < ai} ∩ {Zi < bi}}. (2.3.5)
where βi, ai and ai−1 are fixed. This is a standard computation for deriving group
sequential designs that is outlined in Jennison and Turnbull (2000). With the repa-
rameterization from ai and bi to αi(0) and βi(0) we now have a method of choosing
designs that control Type I error.
Next we consider sample size parameterization to control power. We let ri =
ni/n1 > 1 represent the relative increase in sample size at the second stage of the
trial based on interim results at stage 1, i = 2, 3, . . . ,m. The initial parameters
defining the distribution were n1, . . . , nm, a1, . . . , am, b2, . . . , bm. Note b1 = am in this
two-stage design setting. Thus, there were a total of 3m − 1 parameters defining
the design. The complete reparameterization now consists of n1, α, ri, αi(0) and
βi(0), i = 2, 3, . . . ,m, which still has 3m − 1 parameters. Any two designs with all
parameters other than n1 equal will have the same Type I error structure. The power
to reject θ = 0 when, in truth, θ = δ > 0, 1− β(δ), is strictly increasing as a function
of n1 in this case. δ represents the minimal treatment difference of interest. A root
finding algorithm can find a minimum value of n1 that provides a desired power level.
Thus, we can replace n1 with β(δ) in the parametrization.
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2.4 Unrestricted 2-stage designs
An appropriately selected and unrestricted parameter space can make optimiza-
tion problems particularly tractable. We develop an unrestricted reparameterization
of the design. We assume α and β(δ) are fixed at desired levels. It may be easier to
optimize the unrestricted value n1 rather than β(δ) if power is not restricted. Note
that we are treating n1 as a proportion of the sample size of a fixed design (nfix) with
Type I error α and power 1-β(δ), and thus as a continuous variable rather than as an
integer value here.
We consider a real value xai and let
αi(0) =
α exp(xai)
1 +
∑m
j=2 exp(xaj)
(2.4.1)
i = 2, 3, . . . ,m. Similarly, we consider a real value xbi and let
βi(0) =
(1− α) exp(xbi)
1 +
∑m
j=2 exp(xbj)
(2.4.2)
i = 2, 3, . . . ,m. Note that
α1(0) =
α
1 +
∑m
j=2 exp(xaj)
, (2.4.3)
and
β1(0) =
1− α
1 +
∑m
j=2 exp(xbj)
, (2.4.4)
Finally, we consider a real value xri and let ri = 1 + exp(xri), i = 2, 3, . . . ,m.
Now our parameter space consists of fixed values α and β(δ) and 3m− 3 unrestricted
parameters: xai, xbi, and xri, i = 2, 3, . . . ,m. This space is easily mapped to the error
13
probability parameter space and then to the appropriate boundary cutoffs. A simple
optimization function such as the R nlminb function can be used to find a design to
minimize the expected sample size given a fixed Type I error, power and δ value.
2.5 Results
2.5.1 Stepwise Adaptive Design Characteristics
The fully optimized two-stage design from Lokhnygina and Tsiatis (2008) suggests
that the sample size for the second stage is an inverted ‘U’ shape curve of the test
statistic from the first stage to achieve the minimum expected sample size over a
range of alternatives. Posch et al. (2003) also suggests a similar shape of the optimal
second-stage polynomial while minimizing expected sample size averaged over some
fixed alternatives, i.e., only upsizing the trial when the treatment effect in the first
interim is an intermediate effect furthest from stage one boundaries.
In light of the inverted ‘U’ shape curve from Lokhnygina and Tsiatis (2008) design,
we present the stepwise adaptive design, which is an optimal design with two choices
of second-stage sample sizes with m = 4. We set the choice of second-stage sample
size to one value when the first-stage test statistic is close to either the futility bound
or efficacy bound at the first interim, i.e., n2 = n4. The other choice of sample size is
chosen when the first-stage test statistic falls into an intermediate region away from
the first-stage stopping boundaries, i.e., an intermediate treatment effect is observed
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that is not particularly close to the null or alternate hypothesis effect size. This feature
can further blind the treatment effect at the first interim analysis. The expected
sample size was integrated over a normal prior distribution for θ with mean and
standard deviation δ/2. The prior mean might be chosen based on the best knowledge
of the treatment effect before the trial started. The prior standard deviation might
be chosen to reflect the range of the interest. The specific choice of δ/2 was arbitrary.
We’ll show the results later about the impact of the choice of the prior mean and
standard deviation on the optimization of the trial design. The second-stage sample
sizes and the cutoffs for selecting among stage two sample sizes were selected through
the optimization algorithm which minimizes the expected sample size. The first-stage
sample size was selected to produce the desired power 1− β(δ).
Figure 2.1 (top) shows the stepwise adaptive design, the fully optimized two-
stage adaptive design (Lokhnygina and Tsiatis (2008)) and optimal two-stage group
sequential designs (Anderson (2007)). We focus on the proposed stepwise adaptive
design first. The top left figure shows total sample size N for the optimal design
expressed as a percentage of the fixed sample size design, Nfix, as a function of the
standardized statistic at first interim analysis, Z1. The top right figure shows the
boundary value at the second stage, Z2, as a function of Z1. For error probabilities
α = 0.05 and β = 0.1, Nfix = (1.64 + 1.28)/δ
2 and the boundary for a one stage
study would be Φ−1(0.95) = 1.64. In this two-stage design, the first interim analysis
would be conducted after 0.52Nfix observations. If the standardized test statistic Z1
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is less than 0.48 then the trial will stop for futility. If the standardized test statistic
Z1 exceeds 2.01, the trial will stop for efficacy. If the standardized test statistic Z1
falls into the region [0.69, 1.70], the final total sample size would be 1.20Nfix and the
second-stage boundary would be 1.75. Otherwise, if the standardized test statistic Z1
falls into the other area of the continuation region, the final total sample size would
be 1.07Nfix. and the second-stage boundary is 1.67.
While Figure 2.1 (top) also compares the study designs from this stepwise adaptive
design with the fully optimized two-stage adaptive design (Lokhnygina and Tsiatis
(2008)) and optimal two-stage group sequential designs (Anderson (2007)). The step-
wise adaptive design gives two choices of second-stage sample size: the total sample
size close to the sample size from a fixed design when the first interim test statis-
tic is close to the futility bound or efficacy bound; the total sample size increases
about 20% compared to the sample size from a fixed design when the first interim
test statistic is intermediate. The stepwise adaptive design is simplified compared to
the fully optimized two-stage adaptive design. Comparing to the optimal two-stage
group sequential design, the stepwise adaptive design has the sample size and bound-
ary close to the fixed sample size design when the interim test statistic is close to the
first-stage boundaries. The maximum sample size and corresponding second-stage
boundary from stepwise adaptive design is a bit higher compared to group sequential
design but not much higher. Knowing the sample size adaptation following stage 1
reveals some information about the interim test statistic which, in turn, can be trans-
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Figure 2.1: Total sample size N/Nfix (top left) and the boundary value (top right)
at the second stage for designs optimized for prior θ ∼ N(δ/2, (δ/2)2) with 90%
power and 5% Type I error, one-sided; expected sample size (middle left), power
(middle right), predictive power (bottom left), probability of maximizing N after first
interim analysis (bottom right) over a range of θ for the design optimized for prior
θ ∼ N(δ/2, (δ/2)2).
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Table 2.1: How stage 2 sample size knowledge translates into possible stage 1 results
by design type for optimal designs with prior θ ∼ N(0, (δ/2)2), 90% power and 5%
Type I error, one-sided
Examples of stage two sample size relative to the fixed design Possible values of Z1
Stepwise Adaptive Design
0.68 (0.69, 1.70)
0.55 (0.48, 0.69), (1.70, 2.01)
Fully Optimized Adaptive Design
0.71 1.18
0.49 0.47, 1.94
Optimal Two-Stage Group Sequential Designs
0.65 (0.50, 1.99)
lated into an approximate range for the interim observed treatment effect. Table
2.1 shows the examples of the range of possible Z-values that correspond to different
known stage 2 sample sizes.
Figure 2.1 (middle and bottom) compares the expected sample size, overall power,
and predictive power of this stepwise adaptive design with the fully optimized two-
stage adaptive design and optimal two-stage group sequential designs. The stepwise
adaptive design had nearly identical expected sample size and overall power over a
range of alternatives compared to the fully optimized two-stage adaptive design and
optimal two-stage group sequential designs. Predictive power is defined as a weighted
average of conditional power (conditioning on the first-stage test statistic) with prior
θ ∼ N(δ/2, (δ/2)2). The stepwise adaptive design and fully optimized adaptive design
have higher predictive power when the first-stage test statistic is close to the upper
efficacy bound and lower predictive power when the first-stage test statistic is close
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to the lower futility bound compared to optimal two-stage group sequential design.
We also compare the probability of maximizing sample size for the stepwise adaptive
design and the optimal two-stage group sequential design. The stepwise adaptive
design has a lower probability of requiring the maximum total sample size compared
to the optimal two-stage group sequential design as shown in Figure 2.1 (bottom
right), though the maximum sample size is a bit larger for the stepwise adaptive
design.
The designs shown above are based on a prior distribution of θ ∼ N(δ/2, (δ/2)2),
which is the situation when the investigator has some prior information and is neutral
on treatment effect between the null and alternative hypothesis. Early Phase II
development of experimental drugs might fit this situation. We also explored the
stepwise adaptive design which uses different prior distribution. Figure 2.2 (top)
shows the design with prior θ ∼ N(0, (δ/2)2) and Figure 2.2 (middle) shows the
design with prior θ ∼ N(δ, (δ/2)2). With prior mean =0, the experimenter does
not have much confidence in the treatment effect; the stepwise adaptive design only
increases the sample size when the interim statistics looks promising. With prior
mean =δ, the experimenter has more confidence in the treatment effect, the stepwise
adaptive design only increases the sample size when the interim test statistic does
not look promising. We also investigate the impact of a flatter prior distribution on
the design. Figure 2.2 (bottom) shows the design with prior θ ∼ N(δ/2, (2δ)2) vs.
θ ∼ N(δ/2, (δ/2)2). The stepwise design with a flatter prior has a wider continuation
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region and an earlier first interim analysis which would be conducted after 0.29Nfix
observations. This is inconsistent with common recommendation of conducting the
first interim analysis at around 50% information time. This suggests that the time
to adapt also depends on how much prior information we have. For many trials
with delayed endpoints, the only possible time for adaptation would be at early time
points.
2.5.2 Stepwise Adaptive Design Compares with Designs Based
on Promising Conditional Power
Chen et al. (2004) showed that the conventional test could be performed without
inflating the Type I error if one increased the sample size only when interim results
were promising, which was defined as conditional power of 50 percent or greater. Gao
et al. (2008) and Mehta and Pocock (2011) further extended this idea to a broader
range of promising zones in which the sample size may be increased up to an upper
bound based on conditional power and the conventional tests may be applied without
inflating Type I error.
Define z1 as the first-stage test statistic, n˜2 as the incremental sample size at
the second stage, and δˆ1 as the observed treatment effect at stage 1. Mehta and
Pocock (2011) partitioned the conditional power value, CPδˆ1 (z1, n˜2), into three zones:
unfavorable zone, promising zone and favorable zone. CPδˆ1 (z1, n˜2) < CPmin defined
the unfavorable zone, while CPmin depends on nmax/n2, n1/n2 and 1−β, which means
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that the interim result is so disappointing that it is not worth increasing the sample
size. CPmin ≤ CPδˆ1(z1, n˜2) < 1− β defined the promising zone, with results that are
not disappointing but not good enough for the conditional power to equal or exceed
the unconditional power specified at the design stage. CPδˆ1(z1, n˜2) ≥ 1 − β defined
the favorable zone, in which the interim results are favorable. This approach can be
extended to a two-stage group sequential design with possible early stopping at stage
one. We present the stepwise adaptive design with the constraint of n1/n2 = 0.5
and Gao’s method on two-stage group design where nmax/n2 = 2, n1/n2 = 0.5 and
1 − β = 0.9 in Figure 2.3 (left). The sample size in Gao’s adaptive design is up to
double the sample size of the two-stage group sequential design when the interim test
statistic is in the promising zone. We also compare the second-stage critical values
for different designs. Mehta and Pocock (2011) mentioned that the Type I error was
preserved even when the conventional test was performed, and suggested using the
second-stage boundary of the unfavorable zone/the favorable zone for the promising
zone. Figure 2.3 (right) shows the observed treatment effect at the study boundary
when the trial is stopped for designs with α = 0.05. The observed treatment effect
at the boundary of Gao’s adaptive design is much smaller than the stepwise adaptive
design due to the big sample size increase in the promising zone even if we use the
conventional test. Figure 2.4 show the power and expected sample size from the
stepwise adaptive and Gao’s adaptive design. When we match the power of the
stepwise adaptive design with Gao’s adaptive design at 0.5δ, the power is higher for
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Figure 2.3: Total sample size N/Nfix (left) and observed treatment effect at study
boundary (right). Stepwise adaptive design and Gao’s adaptive designs have n1/n2 =
0.5, the stepwise adaptive design is optimized for prior θ ∼ N(δ/2, (δ/2)2), and the
maximum sample size for Gao’s adaptive design can be up to double the size of the
sample size for a two-stage group sequential design to have 90% conditional power
when the first-stage test statistic fall into promising zone.
the stepwise adaptive design if the true mean is δ and the expected sample size is
generally smaller for the stepwise adaptive design.
2.6 Discussion
Lokhnygina and Tsiatis (2008) presented a fully optimized two-stage design that
has minimum expected sample size averaged over a range of alternatives. In this
paper, we simplified this design and presented a method to create a pre-specified
optimal two-stage design with a limited set of stage two sample size possibilities to
lessen the information revealed at the interim analysis.
In this paper, we focus the stepwise adaptive design with two choices of second-
stage sample size for the prior distribution of θ ∼ N(δ/2, (δ/2)2). We set the choice
of second-stage sample size to one value when the first-stage test statistic is close to
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either the futility bound or efficacy bound at the first interim analysis, i.e., n2 = n4,
and to a different value when the first-stage test statistic falls into an intermediate
region away from the first-stage stopping boundaries, i.e., an intermediate treatment
effect is observed that is not particularly close to the null or alternate hypothesis effect
size. This feature of the design improves blinding of the interim treatment effect by
lessening the information revealed at the interim analysis. Each second-stage sample
size corresponds to one range or two ranges of the first interim analysis test statistic,
as shown in Table 2.1. If the study proceeds to the second stage with sample size of
0.68Nfix, we know only that the standardized first-stage test statistic is between 0.69
and 1.70. If the study proceeds to the second stage with sample size of 0.55Nfix, we
know only that the standardized first-stage test statistic is either between 0.48 and
0.69 or between 1.70 and 2.01. The fully optimized two-stage adaptive design has
unlimited choices of second-stage sample size due to its continuous nature and could
therefore reveal one or two exact first interim analysis test results given the choice
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of second-stage sample size. The optimal two-stage group sequential design has only
one choice of second-stage sample size and reveals the least information (only gave
one range of first-interim analysis test statistic). The stepwise adaptive design and
the optimal two-stage group sequential design therefore reveal less information about
the interim treatment effect than the fully optimized adaptive design.
We have seen that the efficiency loss from the stepwise adaptive design may be min-
imal compared to the substantially more complicated fully optimized design (Lokhny-
gina and Tsiatis (2008)). The stepwise adaptive, fully optimized adaptive designs and
optimal two-stage group sequential designs have similar expected sample size and
overall power over the range of θ. Advantages of the stepwise adaptive design over
the optimal two-stage group sequential design are that the minimum second-stage
sample size is much smaller, and the stepwise adaptive design is less likely to require
the maximum sample size compared to the optimal two-stage group sequential design.
Notice the shape of the stepwise adaptive design is not symmetric. This is also true
for the fully optimized two-stage adaptive design (Lokhnygina and Tsiatis (2008)).
This might be caused by the optimization process which requires a minimum expected
sample size for a given prior. We design a symmetric stepwise adaptive design with
equal length of continuation region when the first-stage test statistic is close to the
futility bound or efficacy bound at the first interim. We compare the expected sample
size for the current stepwise adaptive design with this symmetric stepwise adaptive
design. The expected sample size for the current stepwise design relative to a fixed
25
sample size design is 0.77096 compared to 0.77107 for the symmetric stepwise adaptive
design.
Levin et al. (2011) recently presented a completely pre-specified optimal adaptive
design. This design is similar to our stepwise adaptive design in that we both used step
functions. Levin et al. (2011) only considered the symmetric design and optimized the
design by assigning half the weight on the null and half the weight on the alternative
and achieved the optimization through adding more steps to the design. Our design
focuses on the design with fewer steps and minimizes the expected sample size over
a range of alternatives.
Chuang-Stein et al. (2006) pointed out that the interim treatment effect size can
be highly variable and potentially too unreliable to be used directly for sample size
re-estimation purposes. And in general, the sample size re-estimation design based
on conditional power is likely not optimized for expected sample size. Jennison and
Turnbull (2003) have demonstrated that mid-course sample size modification based
on the observed treatment effect come with the cost of efficiency when compared with
group sequential designs. The stepwise adaptive design is an extension of standard
group sequential design. This design is pre-specified at the design stage as the group
sequential design and also provides the opportunity of sample size adaptation with
great efficiency. The stepwise adaptive design provides a solution by combining the
prior information and the information within a trial.
We have found our stepwise adaptive design is competitive with fully optimized
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two-stage adaptive and with optimal two-stage group sequential designs, but reveals
less information about interim treatment effect than the fully optimized adaptive
design and has the potential to increase sample size based on interim results.
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Chapter 3
Sample Space Ordering and
Inference for Group
Sequential/Adaptive Designs
3.1 Introduction
Armitage, McPherson, and Rowe (1969) numerically showed that if significance
tests at a fixed level are repeated at interim analyses, the Type I error rate (or α) is
greatly increased over the nominal level. Simple group sequential methods for a pre-
defined number of equally spaced interim analyses were developed by Pocock (1977)
and O’Brien and Fleming (1979) to control the Type I error rate by adjusting the
critical values. Wang and Tsiatis (1987) generalized Pocock (1977) and O’Brien and
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Fleming (1979) designs to a class of group sequential tests, also referred as boundary
families. But the boundary family designs assume the maximum number of analyses,
K, be fixed in advance and require equally spaced interim analyses. Lan and DeMets
(1983) suggested an alternative method to construct discrete sequential boundaries
by using α-spending functions. The boundary at a decision time is determined by
α(t), where t is the timing of the interim analysis, which is also called information
time. Information time t is defined as Ii/Imax for i = 1, . . . , K, where Ii is the
statistical information at analysis i and Imax represents the maximum planned infor-
mation at the time of design. Kim and DeMets (1987) and Hwang, Shih, and DeCani
(1990) individually extended the method of Lan and DeMets (1983) to a general one-
parameter family of α-spending functions, α(t; γ) = α × hγ(t), where the parameter
γ specifies the rate of α-spending. The function h(t) is increasing in t ∈ (0, 1) with
h(0) = 0 and h(t) = 1 for t ≥ 1. Pampallona, Tsiatis, and Kim (2001) extended
the Type I error spending method of Lan and DeMets (1983) by incorporating an
analogous Type II error (or β) spending function for interim analyses to test futility.
Anderson and Clark (2010) discussed additional one- and two-parameter spending
families. Their two- or three-parameter spending function families provide additional
flexibility to customize the shape of spending functions to fit more than one desired
critical value. The spending function approach has become common because of its
flexibility in accommodating unequally-spaced analyses and allowing some leeway in
moving, adding or deleting interim analyses as long as this is done without knowledge
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of treatment effects. This is compared to boundary families which require a fixed total
number of analyses, generally performed at equally-spaced intervals. The boundaries
constructed by α- and β- spending functions are determined by the past and current
information times but not by future information times, and not by the total number
of analyses. These are the properties of the spending function approach that allow
flexibility in resetting timing of analyses during the course of the trial.
Group sequential designs with asymmetrical boundaries permit clinical trial stop-
ping for efficacy when the interim results cross the upper boundaries or stopping for
futility when the interim results cross the lower boundaries. Boundaries of the group
sequential design define the acceptance or rejection of the null hypothesis of the group
sequential test on their own, however the boundaries do not provide additional in-
formation about the relative strength of the evidence to reject the null hypothesis.
For i = 1, 2, . . . , K, let Zi be the test statistic against the null hypothesis H0 in favor
of the alternative hypothesis H1 at analysis i. Let Ci be the continuation region at
analysis i and CK = ∅. Ω is the sample space defined by a classical group sequential
design, that is, the set of all pairs (i, zi) where zi /∈ Ci so that the test can terminate at
stage i with (T, ZT ) = (i, zi). A p-value for testing H0 can be stated as the probability
under the null hypothesis of obtaining (i, zi) as extreme or more extreme than the
observed (i∗, z∗i ), where “extreme” refers to the ordering of Ω. A fixed sample design
(with no monitoring) has unique ordering of the sample space under the normality
assumption due to the monotone likelihood ratio property. The p-value converges to
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0 as z → ∞, and the p-value converges to 1 as z → −∞ for a fixed sample design.
But this is not the case for a group sequential trial. Since the number of observations
varies between different stages, there are many ways to order the possible outcomes.
We start with a brief review of the basic concepts of group sequential testing
and existing sample space orderings for group sequential designs, including stage-
wise ordering by Tsiatis, Rosner and Mehta (1984); maximum likelihood estimate
(MLE) ordering by Emerson and Fleming (1990); likelihood ratio ordering or z-score
ordering by Chang (1989); score test ordering or B-value ordering by Rosner and
Tsiatis (1988), and sequential p-value ordering by Liu and Anderson (2008a). We
prefer to use sequential p-value ordering because this method uses the totality of
the accumulating data which takes into account the entire sample path, while the
other orderings only consider the data where the boundary was crossed or the data
at the current analysis. We will show that spending functions with the form of
α(t) = α × h(t) do not completely order the sample space using the power spending
function as an example. This has the disadvantage that there is often a broad range
of the sample space at an interim analysis where the p-value is 1. The exponential
spending function from Anderson and Clark (2010), αe(t; ν) = α
t−ν , has a different
form from most commonly used spending functions. We will define what we mean
by the complete ordering of a group sequential sample space and show that a Wang-
Tsiatis boundary family or an exponential spending function family or Lan-DeMets
O’Brien-Fleming approximation can completely order the sample space. We also
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propose a simple method to transform a spending function to a completely ordered
sample space when using the sequential p-value ordering, a power spending function
will be used as an example. This method is also extended to β-spending functions
for p-values to reject the alternate hypothesis. We’ll then give examples to illustrate
our approach.
3.2 Review of Group Sequential Testing
Consider a group sequential trial with K > 1 analyses which generates the se-
quence of test statistics Z1, Z2, . . . , ZK . Let θ represent the single parameter of inter-
est, which is the treatment effect in our case. The amount of statistical information
about θ at analysis i is denoted by Ii, i = 1, 2, . . . , K, with 0 < I1 < I2 < . . . < IK .
In many situations Ii is proportional to the number of observations (or events) at
interim analysis i, i = 1, 2, . . . , K. Assume that the distribution of test statistics
Z1, Z2, . . . , ZK for the K analyses follows a multivariate normal distribution with
E{Zi} = θ
√
Ii, (3.2.1)
Cov(Zj, Zi) =
√
Ij/Ii (3.2.2)
for 1 ≤ j ≤ i ≤ K. Jennison and Turnbull (2000) refer to this as the ‘canonical form’
for group sequential designs.
We consider testing the null hypothesis H0 : θ = 0 against the alternative H1 : θ =
δ for a fixed δ > 0 with one-sided Type I error probability α and power 1−β at θ = δ.
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Let Ci be defined as the continuation region at stage i, i.e., Ci =
⋂i
j=1{aj ≤ Zj < bj},
for i = 1, . . . , K − 1. Note that CK = ∅ with aK = bK . Let ai be the lower boundary
and it is also called the futility boundary. Let bi be the upper boundary and it is also
called the efficacy boundary. For i = 1, . . . , K − 1, the trial is stopped for efficacy at
the ith interim analysis to reject H0 if Zi ≥ bi, is stopped for futility to reject H1 if
Zi < ai, and continues if ai ≤ Zi < bi. At the final analysis, the null hypothesis H0
is rejected if ZK ≥ bK .
First, we consider a binding lower boundary, i.e., the trial must be stopped once
either the upper or the lower boundary is crossed. For i = 1, . . . , K, the probability
of crossing an upper bound at analysis i without previously crossing any bound for
any θ is
αi(θ) = Pθ{{Zi ≥ bi}
i−1⋂
j=1
{aj ≤ Zj < bj}} (3.2.3)
The value αi(0) is commonly referred to as the amount of α (Type I error) spent at
analysis i, for i = 1, . . . , K. The total Type I error for a trial will be denoted by
α(0) ≡∑Ki=1 αi(0).
For i = 1, . . . , K, the probability of crossing a lower bound at analysis i without
previously crossing any bound for any θ is
βi(θ) = Pθ{{Zi < ai}
i−1⋂
j=1
{aj ≤ Zj < bj}}. (3.2.4)
The value βi(δ) is commonly referred to as the amount of β (Type II error) spent at
analysis i, for i = 1, . . . , K. The total Type II error for a trial will be denoted by
β(δ) ≡∑Ki=1 βi(δ).
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Sometimes the futility boundary is considered just a guideline, which means that a
study can continue even though the futility boundary has been crossed with Zi < ai,
for i = 1, . . . , K − 1. The futility boundaries are then called non-binding futility
boundaries. In this case, the boundaries ai and bi are defined by replacing αi(θ) in
(3.2.3) with α+i (θ) where
α+i (θ) = Pθ{{Zi ≥ bi}
i−1⋂
j=1
{Zj < bj}} (3.2.5)
and
α+(θ) ≡
K∑
i=1
α+i (θ). (3.2.6)
.
3.3 Review of Sample Space Ordering
It is important to provide the strength of evidence to reject the null hypothesis H0 :
θ = 0 after a trial is complete or even during a trial. For a trial with no monitoring,
the p-value should be uniformly distributed under H0, i.e., Pr{p-value ≤ p} = p
for all 0 ≤ p ≤ 1. As the z-value increases from −∞ to ∞, Pr(Z > z) decreases
from 1 to 0 for a one-sided test. For a group sequential trial, a p-value for testing
H0 can be stated as obtaining (i, zi) as extreme or more extreme than the observed
(i∗, z∗i ), where “extreme” refers to the ordering of the sample space Ω, which is the
set of all possible outcomes. Let (i′, z′i)  (i, zi) denote that (i′, z′i) is above (i, zi)
in a given ordering. Jennison and Turnbull (2000) and Proschan, Lan and Wittes
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(2006) summarized four sample space orderings by using the value of (i, zi) at trial
termination:
A. Stage-wise ordering by Tsiatis, Rosner and Mehta (1984), (i′, z′i)  (i, zi) if (1)
i′ = i and z′i ≥ zi (2) i′ < i and z′i ≥ bi′ (3) i′ > i and zi ≤ ai.
B. Maximum likelihood estimate (MLE) ordering by Emerson and Fleming (1990),
(i′, z′i)  (i, zi) if z′i/
√
Ii′ > zi/
√
Ii, where Ii is the statistical information.
C. Likelihood ratio ordering or z-score ordering by Chang (1989), (i′, z′i)  (i, zi)
if z′i > zi.
D. Score test ordering or B-value ordering by Rosner and Tsiatis (1988), (i′, z′i) 
(i, zi) if z
′
i
√
Ii′ > zi
√
Ii.
For MLE, z-score, and B-value ordering, the p-value depends on the information
levels or group sizes beyond the observed stopping stage T = τ , while stage-wise
ordering has the property that the p-value does not depend on the information lev-
els or group sizes beyond the observed stopping stage T = τ . Stage-wise ordering
automatically ensures that the p-value is less than the significance level α of the
group sequential test if and only if H0 is rejected. Jennison and Turnbull (2000)
and Proschan, Lan and Wittes (2006) recommended stage-wise ordering. However,
stage-wise ordering also has limitations: (1) Stage-wise ordering does not provide a
p-value when the test statistic has not crossed either boundary. (2) Stage-wise order-
ing does not provide final analysis for data over-running, which might happen due to
additional patient enrolled and staggered data entry after boundary was crossed at
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the interim analysis (although this has been dealt with by Whitehead (1992)). (3)
When a test statistic is on an interim boundary, stage-wise ordering rejects the null
hypothesis at a significance level less than α. (4) A stage-wise p-value can not be
arbitrarily small after the first interim analysis, even if the test statistic is big or
evidence to reject the null is strong; i.e., the p-value for crossing at an analysis after
the first interim is always larger than the nominal p-value for a case where the first
interim bound is crossed.
Liu and Anderson (2008a) introduced an extended group sequential design (EGS
design), which is a group sequential design with the stopping time τ , taking values
of 1, 2, . . . , K. τ may precede, coincide with, or exceed the boundary crossing time.
An EGS test is defined as positive if any interim or final efficacy bound is crossed,
which corresponds to the event
⋃K
i=1[{τ = i}
⋂⋃i
j=1{Zj ≥ bj}] occurs. For an EGS
test indexed by a parameter µ ∈ (0, 1), there exist bi(µ) for i = 1, 2, . . . , K, such that
P0{Z1 ≥ b1(µ)
⋃
Z2 ≥ b2(µ)
⋃
. . .
⋃
ZK ≥ bK(µ)} = µ.
The class of boundaries indexed by µ ∈ (0, 1) is defined as a well-ordered class if the
boundary bi(µ) is continuous and decreasing in µ and converges to ∞ as µ → 0 for
any i = 1, 2, . . . , K.
Liu and Anderson (2008a) considered ordering the sample space using the totality
of the accumulating data. For any sample path ω = {τ ;Z1, . . . , Zτ}, a repeated p-
value is defined as µˆ(i) = sup{µ : Zi ≤ bi(µ)} for i = 1, 2, . . . , τ . A sequential p-value
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is defined as pi = min1≤j≤i{µˆ(j)}. The final sequential p-value is defined as
pτ = min{µˆ(i) : i = 1, . . . , τ}.
Any two sample paths, ω′ and ω′′, are said to follow the order  if and only if their
final p-values, p′τ ′ and p
′′
τ ′′ , follow the order of p
′
τ ′ ≥ p′′τ ′′ . If ω′  ω′′ and ω′′  ω′′′,
then ω′  ω′′′. Thus the ordering is well defined.
The fundamental difference between Liu and Anderson (2008a) sequential p-value
ordering and other orderings including stage-wise, MLE, z-value, and B-value ordering
is that the sequential p-value ordering uses the totality of the accumulating data
which takes into account the entire sample path ω = {τ ;Z1, . . . , Zτ}, while the other
orderings only consider the data where the boundary was crossed {τ ;Zτ} or at the
most recent analysis. Liu and Anderson (2008a) summarized several features of the
sequential p-values: (a) The final p-value, pτ , adheres to the ITT principle that
all available data are analyzed; (b) sample paths reaching the same boundary have
identical p-values; and (c) pτ is always significant if the significance boundary is
crossed at any stage, not requiring Zτ ≥ bτ . We prefer to use sequential p-value
ordering from Liu and Anderson (2008a) because this method uses the totality of the
accumulating data and does not reverse inference once it is made.
3.4 Complete Ordering of Sample Space
To completely order the sample space as the fixed sample design, we define the
class of boundaries as completely ordered if the boundary bi(µ) is continuous and
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decreasing in µ, converging to ∞ as µ → 0, and converging to −∞ as µ → 1 for
any i = 1, . . . , K for a group sequential trial. A completely ordered sample space is
a well ordered sample space, but the reverse is not necessarily true. A sample space
can be well ordered without the boundary converging to −∞ as µ→ 1 for at least 1
i ∈ 1, . . . , K for a group sequential trial.
The Pocock design from the boundary families is an example of complete ordering
of sample space based on a sequential p-value ordering. The sample space in the
boundary scale has complete coverage from −∞ to +∞ in the z-value scale for any
i = 1, . . . , K. And similarly, the sample space has complete coverage from 0 to 1 in
the probability scale for any i = 1, . . . , K. Figure 3.1 gives an example of a Pocock
design with 5 analyses. At the 3rd analysis, the test statistic crossed the boundary
for the pre-specified α = .025. The trial continued after the 3rd interim analysis and
stopped at the 4th interim analysis to collect more safety data. The repeated p-values
were 0.337, 0.098, 0.010, and 0.018, respectively. The sequential p-values were 0.337,
0.098, 0.010, and 0.010. The final sequential p-value was 0.010.
Boundary family tests, e.g., the Wang-Tsiatis family, including Pocock, O’Brien-
Fleming boundary, produce completely ordered sample spaces when using sequential
p-values to order the sample space. But the reduced flexibility of the boundary fam-
ily tests prevents their broader application in real situations, since change the timing
of interim analyses during the trial will result in changing the bounds already used.
The spending function approach has increased popularity since it provides flexibil-
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Figure 3.1: Ordering of Sample Space by total Type I error associated with the bound:
Pocock design with 5 equally spaced interim analyses.
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ity in changing the timing of interim analyses while keeping intact the bounds used
before. Lan and DeMets (1983) introduced spending functions to approximate the
Pocock boundary (α(t) = α(1 + log(1 + (e− 1)t))) and the O’Brien-Fleming bound-
ary (α(t) = 2(1 − Φ(Φ−1(1−α/2)√
t
))). Kim and DeMets (1987) introduced a spending
function based on the power function (α(t, ρ) = αtρ). Hwang, Shih, and DeCani
(1990) proposed a general one-parameter spending function to construct customized
group sequential boundaries (α(t, γ) = α
1−exp(−γt)
1−exp(−γ) ). Anderson and Clark (2010)
introduced an exponential spending function α(t) = αt
−ν
and a general spending
function α(t; ν) = 2(1 − F (F−1(1−α)√
tν
)) (Equation 10 in Anderson and Clark (2010)).
Both O’Brien-Fleming-type spending function and the exponential spending function
are special cases of equation 10 of Anderson and Clark (2010). With the exception of
the exponential family and O’Brien-Fleming-type spending function, other spending
functions have the form α(t) = α × h(t) with t ∈ (0, 1) as the timing of the interim
analysis. We attempt to order a sample space by using spending functions as follows:
set up a spending function for each α level, compute corresponding bounds for each
interim, if an interim or final analysis crosses a bound, it is significant at that level.
We set significance by the ’most significant’ bound reached. This will require that the
spending function produces ordered sets of bounds as we have seen for the Pocock de-
sign where no bounds crossed others. Theorem 1 below gives sufficient conditions for
well ordered sample space and shows that the spending functions like α(t) = α×h(t)
generate well ordered sample spaces when using the sequential p-value to order the
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sample space. Maurer and Bretz (2013) provides similar conditions for well ordered
sample space, in which they call it well ordered families of spending functions and
define that through nominal significance levels at the ith interim analysis rather than
the corresponding boundary values. We define the sample space as well ordered when
the boundary bi(α) is continuous and decreasing in α, converging to ∞ as α→ 0, for
any i = 1, . . . , K for a group sequential test when using sequential p-value to order
the sample space.
Definition 1. A function f(t, α) is a spending function if for some arbitrary
0 < α < 1
• f(0, α) = 0,
• f(t, α) = α for t ≥ 1, and
• f(t, α) is increasing for t > 0.
Definition 2. Assume the canonical form for some K > 1 with 0 < t1 < t2 . . . < tK =
1 and corresponding multivariate normal random variables Z1,Z2,. . .,ZK. Assume
further that for some 0 < α < 1 that f(t, α) is a spending function with f(1, α) = α.
Then bi(α) defined implicitly through
f(t1, α) = Pr{Z1 ≥ b1(α)} (3.4.1)
and
f(ti, α)− f(ti−1, α) = Pr{{Zi ≥ bi(α)}
i−1⋂
j=1
{Zj < bj(α)}} (3.4.2)
i = 2, 3, . . . , K are referred to as spending-function-defined boundaries.
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Since we will consider different values of α, we have used the notation bi(α) rather
than the simpler and more typical bi.
Definition 3. The class of boundaries indexed by α ∈ (0, 1) is defined as a well-
ordered sample space if the boundary bi(α) is continuous and decreasing in α and
converges to ∞ as α ↓ 0 for any i = 1, 2, . . . , K.
Definition 4. If, in addition, bi(α) converges to −∞ as α ↑ 1 for any i = 1, 2, . . . , K,
then it is defined as a completely-ordered sample space.
Theorem 1. Assume the canonical form for some K > 1 with 0 < t1 < t2 . . . < tK =
1 and corresponding multivariate normal random variables Z1, Z2,. . .,ZK. Assume
further that f(t, α) is a spending function with f(1, α) = α for any 0 < α < 1 and
that for i = 2, 3, . . . , K and any 0 < α1 < α2 < 1 that
f(ti, α1)− f(ti−1, α1) < f(ti, α2)− f(ti−1, α2) (3.4.3)
Assume f(ti, α) is continuous and increasing in α for i = 1, 2, . . . , K. Then f(t, α)
defines a well-ordered sample space.
Proof. (proof by induction) Let α1 < α2.
For i = 1, f(t1, α) = Pr{Z1 ≥ b1(α)}, so b1(α) = Φ−1(1− f(t1, α)).
Since f(ti, α) is continuous and increasing in α for i = 1, 2, . . . , K, α1 < α2 =⇒
f(t1, α1) < f(t1, α2) =⇒ b1(α1) > b1(α2).
Now assume the result holds for i − 1 where i > 1. For i = 2, . . . , K, f(ti, α) −
f(ti−1, α) = Pr{{Zi ≥ bi(α)}
⋂i−1
j=1{Zj < bj(α)}}.
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Assume f(t, α) does not defines a well-ordered sample space and bi(α) is not
decreasing in α. Assume bi(α1) = bi(α2) . Since bi−1(α1) > bi−1(α2), Pr{{Zi ≥
bi(α1)}
⋂i−1
j=1{Zj < bj(α1)}} > Pr{{Zi ≥ bi(α2)}
⋂i−1
j=1{Zj < bj(α2)}}
Thus,
f(ti, α1)− f(ti−1, α1) > f(ti, α2)− f(ti−1, α2).
This contradicts equation (3.4.3) the assumption of an increasing α spending. By
induction, f(t, α) defines a well-ordered sample space, i.e., bi(α) is decreasing in α
for i = 1, 2, . . . , K. 
Corollary 2. Assume the canonical form for some K > 1 with 0 < t1 < t2 . . . < tK =
1 and corresponding multivariate normal random variables Z1, Z2, . . .,ZK. Assume
that for 0 < α < 1 that f(t, α) is a spending function, and that f(t1, α) < f(t2, α) <
. . . < f(tK) = α. Assume further that for i = 1, 2, . . . , K that f(ti, α) is continuous
and differentiable in α with
df(ti, α)
dα
> 0
and for i = 2, . . . , K and any α
df(ti, α)
dα
>
df(ti−1, α)
dα
.
Then f(t, α) forms a well-ordered sample space.
Proof. For i = 2, . . . , K, let 0 < α1 < α2 < 1 and 0 < t1 < t2 < 1.
f(ti, α2)− f(ti, α1) > f(ti−1, α2)− f(ti−1, α1).
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Thus, f(ti, α2)− f(ti−1, α2) > f(ti, α1)− f(ti−1, α1). Per Theorem 1, f(t, α) forms a
well-ordered sample space.
Corollary 3. Assume the canonical form for some K > 1 with 0 < t1 < t2 . . . < tK =
1 and corresponding multivariate normal random variables Z1, Z2, . . .,ZK. Assume
h(t) is an increasing function in t with 0 = h(0) < h(t1) < h(t2) < . . . < h(tK) = 1.
Let
f(t, α) = α× h(t).
Then f(t, α) forms a well-ordered sample space.
Proof. f(t, α) = α× h(t). Then, f(t2, α)− f(t1, α) = α× (h(t2)− h(t1))
Since h(t2)−h(t1) > 0, then α1 < α2 =⇒ f(ti, α1)−f(ti−1, α1) < f(ti, α2)−f(ti−1, α2),
for i = 2, 3, . . . , K. Per Theorem 1, f(t, α) forms a well-ordered sample space.
It is a special case of Theorem 1.
Corollary 3 shows that for f(t, α) = α × h(t), as long as h(t) is an increasing
function in t, it is sufficient to conclude that these spending functions define a well-
ordered sample space for any i = 1, . . . , K. But this is not sufficient to conclude that
these spending functions completely order the sample space for any i = 1, . . . , K,
which requires the boundary converges to −∞ as µ→ 1 for any i = 1, . . . , K.
The spending functions with the form of α(t) = α × h(t) does not provide a
complete ordering of the sample space for the entire sample path, e.g., the z-value
does not have complete coverage from −∞ to +∞ for early analysis. The power
family with ρ = 1 (α(t) = αtρ) provides an example sample space ordering as shown
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Figure 3.2: Ordering of Sample Space by total Type I error associated with the bound:
Power spending function with ρ = 1
in Figure 3.2. In this example, at the first interim, the repeated p-value is 1 for any
nominal p-value ≥ 0.2 or the z-value is ≤ 0.84.
On the other hand, the O’Brien-Fleming-type spending function by Lan and
DeMets (1983) as shown in Figure 3.3 provides a complete ordering on both the
z-value scale and the α-spending scale. But there are limitations, too. The shape of
the boundaries or the speed of α spending is fixed, which means it is not flexible to
change the shape of the boundaries or the speed of α-spending. Fortunately, there are
other spending functions which can provide both the flexibility and also completely
order the sample space.
The exponential spending function (αi(ti) = α
t−νi ) has complete coverage of (0,1)
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Figure 3.3: Ordering of Sample Space by total Type I error associated with the bound:
O’Brien-Fleming-type spending function
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for α, and the z-value has complete coverage from −∞ to +∞ for any i = 1, . . . , K.
And the exponential spending function can change the shape of the boundary to
provide flexibility by modifying the parameter ν. Figure 3.4 gives the cumulative α
spending function and boundary for the exponential spending function with param-
eter ν = 0.8. For α = 0.025, Anderson and Clark (2010) showed that this spending
function approximates the O’Brien-Fleming boundaries. Figure 3.5 provides the cu-
mulative α spending function and boundary for the exponential spending function
with parameter ν = 0.2, which approximates Pocock boundaries for small α. We
can also show by example that the exponential spending function family completely
orders the sample space: the boundaries bi(α) are continuous and decreasing in α,
converging to∞ as α→ 0, and converging to −∞ as α→ 1 for any i = 1, . . . , K; see
Figure 3.6 for ν = .8.
The power spending function and the Hwang-Shih-DeCani spending function are
used widely to calculate spending function boundaries because they provide great
flexibility for clinical trial design. It would be nice to retain the integrity of the
boundary shape at the pre-specified significance level and to have the boundaries
completely cover the sample space when using sequential p-value to order the sample
space.
In the following we propose a method to transform the spending function f(t, α) =
α × h(t) at a pre-specified significance level α0 to a new spending function family
g(t, ρ), which defines a completely ordered sample space when using sequential p-
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Figure 3.4: Ordering of Sample Space by total Type I error associated with the bound:
Exponential Spending Function with ν = 0.8, which approximates O’Brien-Fleming
boundary
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Figure 3.5: Ordering of Sample Space by total Type I error associated with the bound:
Exponential Spending Function with ν = 0.2, which approximates Pocock boundary
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Figure 3.6: Boundaries as a function of Type I error: Exponential Spending Function
with ν = 0.8, which approximates O’Brien-Fleming boundary
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values as defined by Liu and Anderson (2008a). This will also provide a method of
forming confidence intervals.
Conjecture 4. Assume the canonical form for some K > 1 with 0 < t1 < t2 . . . <
tK = 1 and corresponding multivariate normal random variables Z1, Z2, . . .,ZK. As-
sume α0 is pre-specified significance level for a group sequential test and f(t, α0) =
α0×h(t) is the pre-specified increasing spending function in t with 0 < h(t1) < h(t2) <
. . . < h(1) = 1. We define
g(t, ρ;α0) = (f(t, α0)logρ/logα
0
(3.4.4)
with 0 < ρ < 1 and a family of boundary crossing probabilities
g(ti, ρ)− g(ti−1, ρ) = Pr{{Zi ≥ b∗i (ρ)}
i−1⋂
j=1
{Zj < b∗j(ρ)}} (3.4.5)
Then g(t, ρ) defines a completely-ordered sample space. When ρ = α0, g(t, ρ) =
f(t, α0).
We show below that specific definition of
α∗(ρ) = g(t, ρ)
= (f(t, α0)logρ/logα
0
= (α0 × h(t))logρ/logα0
= ρ× h(t)logρ/logα0
can completely order the group sequential design sample space for a pre-specified
spending function f(t, α) = α×h(t), with α0 as a pre-specified significance level. And
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ρ can be interpreted as α∗, which can be directly used as the sequential p-value to or-
der the sample space. When ρ = α0, α∗(ρ) = ρ×h(t)logρ/logα0 = α0×h(t) = f(t, α0).
Thus the boundary by equation 3.4.5 would be the same as the boundary by the pre-
specified spending function f(t, α) at the level α0, which then retain the integrity of
the boundary shape at the pre-specified significance level.
We use the power spending function as an example. For a group sequential design,
the power spending function with parameter ρ = 1, α(t) = α × t, and significance
level of 2.5 percent are selected to design the clinical trial with 5 interim analyses.
Then the efficacy boundaries can be calculated for α0 = 0.025. Figure 3.2 showed
that the z-value does not have complete coverage from −∞ to +∞ for early anal-
ysis. The spending function of α(t) = α × t cannot completely order the group
sequential design sample space. However, we can introduce a specific definition of
α∗(t) = (α0 × t)logα∗/logα0 = α∗ × tlogα∗/logα0 to completely order the sample space
as shown in Figure 3.7. When α∗ = α0 = 0.025, the boundary defined by the spend-
ing function of α∗ is the same as the boundary defined by α0 = 0.025. So the specific
spending function of α∗ keeps the integrity of the efficacy boundary of the pre-specified
significance level α0. And the spending function of α∗ completely orders the sample
space in the z-value scale and the cumulative α∗-spending scale. This can also be
illustrated by Figure 3.8, which shows b∗i (α
∗) as a function of α∗. For each interim
analysis, the z-value has complete coverage.
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Figure 3.7: Ordering of Sample Space by total Type I error associated with the bound:
Power Family with ρ = 1 and α0 = 0.025
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3.5 Illustrative Example
We use the example from Liu and Anderson (2008a) to illustrate how to use the
exponential spending function and the transformation of the spending function α(t) =
α×h(t) to completely order the sample space and get sequential inference. Nosocomial
Pneumonia (NP) is the second most common nosocomial infection after urinary tract
infection, and is the most common infection in the intensive care unit setting. The
clinical cure rate is around 50% with existing options of various antibiotics. The
mortality rate for NP exceeds 30%. Now consider a clinical trial to evaluate whether
a new regimen can improve the clinical cure rate over an existing regimen. It’s also
important to evaluate mortality. A group sequential design is a suitable option,
because the primary endpoint is readily evaluated over 14 days, and the enrollment is
not very rapid. The trial may be continued to allow evaluation of a 30-day mortality
endpoint even though a significance boundary for the primary endpoint has been
crossed. The hypothesized treatment effect sizes are 10% improvement in cure rate for
the new antibiotic and 10% improvement in survival rate. The arcsin transformation
of proportions were employed to apply normal approximation and the effect sizes are
∆1 = 0.1424 and ∆2 = 0.1124. K=10 analysis are planned. The power spending
functions α(i/K)ρ and β(i/K)η for i = 1, 2, . . . , K,α = 0.025 and β = 0.1, are used
to calculate the efficacy and futility boundaries. For the cure endpoint, ρ1=2 and
η1=4 are set. For the mortality endpoint, ρ2 = 4 and η2=2 are set.
We use the 2nd data set generated randomly by Liu and Anderson (2008a) under
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the parameter configuration ∆1 = 0.1424 and ∆2 = 0. We re-analyze these data using
an exponential spending function with parameter ν = 0.8 and a spending function
of α∗ = (α0t)logα
∗/logα0 , with a pre-specified significance level α0 = 0.025. Table
3.1 gives the results of sequential inference as well as the results from the authors.
The mortality endpoint crosses the futility boundary at the third interim analysis.
The trial continues to the fifth analysis, where the primary endpoint crosses the
significance boundary. For the primary endpoint, the sequential p-value provided by
the power spending function is 1.000 for the 1st interim analysis, while the sequential
p-values provided by the exponential spending function and the spending function
of α∗ = (α0t)logα
∗/logα0 are less than 1.000, due to the completely ordered sample
space by the exponential spending function and the α∗-spending function. When
α∗ = α0 = 0.025, the boundary using the spending function of α∗ is the same as the
boundary defined by α0 = 0.025. This property guarantees that the boundary defined
by the α∗-spending function will be crossed whenever the designed boundary at the
pre-specified significance level is crossed. This can be verified by the closeness of
the sequential p-values of the power spending function and the α∗-spending function
at the 5th interim analysis, which are 0.010 and 0.012, respectively. Data from the
primary endpoint illustrate the situation when the drug is efficacious for the cure
endpoint. Data from the secondary endpoint illustrate the situation when the drug is
not effective for the mortality endpoint. The sequential p-values from power spending
function are 1.000 for all interim analyses, because the power spending function could
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Table 3.1: Sequential Inference for Nosocomial Pneumonia (NP) Study
Analysis (i)
1 2 3 4 5 6
Primary endpoint
b1i 3.481 3.152 2.951 2.794 2.661 2.545
Z1i 1.355 1.950 2.333 2.472 2.982 3.220
a1i -3.188 -2.087 -1.320 -0.694 -0.148 0.346
p1i 1.000 0.730 0.144 0.061 0.010 0.003
pe1i 0.680 0.366 0.175 0.095 0.0247 0.008
p∗1i 0.339 0.174 0.080 0.049 0.012 0.004
Secondary endpoint
b2i 4.565 3.957 3.571 3.272 3.020 2.796
Z2i -0.516 -0.505 -1.104 -1.163 -0.626 -0.847
a2i -2.000 -1.173 -0.586 -0.101 0.322 0.703
p2i 1.000 1.000 1.000 1.000 1.000 1.000
pe2i 0.944 0.937 0.989 0.994 0.951 0.980
p∗2i 0.902 0.960 0.998 0.999 0.987 0.997
b1i efficacy boundary, Z1k observed test statistics, a1k futility boundary
p1i sequential p-value from power spending function
pe1i sequential p-value from exponential (O’Brien-Fleming-type) spending function
p∗1i sequential p-value from spending function of α
∗(t) = (α0t)logα∗/logα0
not completely order sample space. Both the exponential spending function and the
α∗-spending function provide proper sequential p-values at all interim analyses. For
the primary analyses, the sequential p-values given here are a good caution to not
stop the trial early; for instance, at interim 3, the nominal p-value for z = 2.333 is
0.01 while for each of the example sequential p-values we are not close to the required
0.025 required for a positive efficacy finding. The large p-values near 1 are perhaps
not terribly useful here. Because of this, we continue to the next section where we
define p-values for futility analyses.
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3.6 Sample Space Ordering for β-Spending Func-
tion
For a fixed sample size design, a Type II error, β, refers to the probability of
failing to reject a false null hypothesis. Pampallona, Tsiatis, and Kim (2001) extend
the Type I error spending method of Lan and DeMets (1983) by incorporating an
analogous Type II error spending function for interim to test futility, which attempts
to reject H1: θ = δ in favor of H0: θ < δ.
Sequential p-values for the α-spending function provide the evidence to reject
the null hypothesis, when they are used to order the sample space. Setting up an
approach to β-spending that has the opposite one-sided orientation to α-spending
is logically consistent with a different sample space ordering for the futility question
than for the efficacy question. It would be of interest to develop a similar sequential
p-value to reject the alternative hypothesis.
Under the framework of Liu and Anderson (2008a) extended group sequential
design, it is noticeable the one-sided nature of the sample space ordering done with
α-spending with a futility boundary considered as “non-binding”. We also notice that
the boundaries are often asymmetric due to different levels of urgency and stringency
to reject the null versus alternative hypothesis. We should note that often testing
is asymmetric and an approach using two one-sided tests (Schuirmann (1987)) is
common. In the TOST (two one-sided test) framework, the alternative test is rejecting
the alternative hypothesis H1 in favor of the null hypothesis H0. We do not generally
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need a lot of evidence for H0, just a lack of evidence for H1. On the other hand,
substantial evidence is normally required to reject the null hypothesis H0.
For testing futility or β-spending, lower boundary crossing probabilities are testing
against H1 rather than H0 and we can use a different spending function and error
level for futility than that is used for efficacy. We want to stop early for futility
without positive evidence of benefit - this results in aggressive early spending which
is associated with less early evidence required to get a small p-value for rejecting H1.
Under the sample space ordering for β-Spending, We consider the bound for re-
jecting H1 in favor of H0 “non-binding” in order to use logic that is consistent with
that used for rejecting the null hypothesis. Note that α+i (0) and bi are defined in
equations (3.2.5) and (3.2.6). Given β+i (δ), ai are defined implicitly by the following
equations:
β+i (δ) = Pδ{{Zi < ai}
i−1⋂
j=1
{Zj ≥ aj}}. (3.6.1)
β+(δ) ≡
K∑
i=1
βi(δ). (3.6.2)
where Zi are the cumulative test statistics for i = 1, . . . , K− 1. Since efficacy bounds
are generally stringent, the value of β+(δ) will often be close to β(δ), which is defined
in equation (3.2.4).
Similar to sample space ordering by α-spending function, an exponential spending
function can completely order the sample space by β-spending function as shown in
Figure 3.9, which shows the futility boundary as a function of Type II error for expo-
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Figure 3.9: Boundaries as a function of Type II error: Exponential Spending Function
with ν = 0.8. The sample size is fixed as the design with α = 0.025 and β = 0.1.
nential spending function with parameter ν = 0.8. As β increases, futility boundaries
increase at each interim increases.
Similarly, β-spending function with the form of β(t) = β × h(t) could not com-
pletely order the sample space by β-spending function. However, we can introduce a
specific definition of β∗ = (β0 × h(t))logβ∗/logβ0 = β∗ × h(t)logβ∗/logβ0 to completely
order the sample space as shown in Figure 3.10, the boundary b∗(β∗) as a function of
β∗. For each interim analysis, the boundary b∗(β∗) has complete coverage.
We use the same example as previous to illustrate sample space ordering by β-
spending. We re-analyze these data under sample space ordering by β-spending using
an exponential spending function with parameter ν = 0.8 and a spending function
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Figure 3.10: Boundaries as a function of Type II error: Power Family with ρ = 1 and
β0 = 0.1. The sample size is fixed as the design with α = 0.025 and β = 0.1.
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of β∗i (t) = (β
0 × h(t))logβ∗/logβ0 , with a pre-specified significance level β0 = 0.1.
Table 3.2 gives the results of sequential inference under sample space ordering by
β-spending. Note that the boundaries and observed test statistics are same for each
interim analysis as those in Table 3.1. We only re-analyze these data under sample
space ordering by β-spending, which is a different orientation from sample space
ordering by α-spending. The mortality endpoint crosses the futility boundary at the
third interim analysis. Of note, while things are trending in the ”wrong” direction
for interims 1 and 2, the evidentiary level given by the sequential p-values suggests
that it is ”too early to give up” and declare futility at that time. The trial continues
to the fifth analysis, where the primary endpoint crosses the significance boundary.
For the primary endpoint, the sequential p-value for β-spending provided by the
power spending function is 1.000 for all interim analyses, because the power spending
function could not completely order sample space. While the sequential p-values for β-
spending provided by the exponential spending function and the spending function of
β∗(t) = (β0×h(t))logβ∗/logβ0 are less than 1.000, due to the completely ordered sample
space by the exponential spending function and the β∗-spending function. Again, for
the secondary endpoint, the sequential p-values for β-spending from power spending
function are 1.000 for the first interim analysis, because the power spending function
could not completely order sample space. Both the exponential spending function and
the β∗-spending function provide proper sequential p-values at all interim analyses.
When β∗ = β0 = 0.1, the futility boundary using the spending function of β∗ is the
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Table 3.2: Sequential Inference under Sample Space Ordering by β-Spending for
Nosocomial Pneumonia (NP) Study
Analysis (i)
1 2 3 4 5 6
Primary endpoint
b1i 3.481 3.152 2.951 2.794 2.661 2.545
Z1i 1.355 1.950 2.333 2.472 2.982 3.220
a1i -3.188 -2.087 -1.320 -0.694 -0.148 0.346
p1i 1.000 1.000 1.000 1.000 1.000 1.000
pe1i 0.925 0.927 0.928 0.892 0.942 0.942
p∗1i 0.906 0.960 0.970 0.950 0.976 0.971
Secondary endpoint
b2i 4.565 3.957 3.571 3.272 3.020 2.796
Z2i -0.516 -0.505 -1.104 -1.163 -0.626 -0.847
a2i -2.000 -1.173 -0.586 -0.101 0.322 0.703
p2i 1.000 0.586 0.022 0.004 0.008 0.001
pe2i 0.630 0.343 0.082 0.024 0.021 0.004
p∗2i 0.378 0.221 0.045 0.015 0.017 0.003
b1i efficacy boundary, Z1k observed test statistics, a1k futility boundary
p1i sequential p-value for β-spending from power spending function
pe1i sequential p-value for β-spending from exponential (O’Brien-Fleming-type)
spending function
p∗1i sequential p-value for β-spending from spending function of
β∗(t) = (β0 × h(t))logβ∗/logβ0
same as the boundary defined by β0 = 0.1.
3.7 Discussion
In this paper, we review the several ways of sample space ordering for group
sequential designs, including stage-wise ordering, MLE ordering, z-score ordering, B-
value ordering and sequential p-value ordering. We prefer to use sequential p-value
ordering from Liu and Anderson (2008a) because this method uses the totality of
the accumulating data and does not reverse inference once it is made. We define
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the complete ordering of a group sequential sample space and show that a Wang-
Tsiatis boundary family or an exponential spending function family can completely
order the sample space. We also show that many popular spending functions, e.g.,
power spending function or Hwang-Shih-DeCani spending function, with the form of
α(t) = α×h(t), do not provide a complete ordering of the sample space for the entire
sample path, e.g., the boundary does not have complete coverage from −∞ to +∞
for early analyses. We propose a simple method to transform a spending function to
a completely ordered sample space when using the sequential p-value ordering. This
method is also extended to β-spending functions for p-values to reject the alternate
hypothesis.
For a group sequential trial with both efficacy and futility boundaries, both the
null and alternate hypotheses can be rejected during the course of a single trial if
both boundaries are crossed (at different times). Using two one-sided sequential p-
values can provide a useful summary of the level of accumulating evidence for and
against both the null and alternate hypotheses as a trial continues. In our example, if
the primary endpoint crossed an efficacy bound and the secondary crossed a futility
bound, we would probably want to stop the trial. On the other hand, if the primary
endpoint crossed the efficacy bound and the secondary endpoint was not yet complete,
the two one-sided sequential p-values provide a summary that may be useful for a
DMC deciding an appropriate action to take.
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Chapter 4
Application of Sequential P-value
Methods to Multiplicity Issues for
Group Sequential Designs
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4.1 Introduction
Multiplicity issues widely exist in clinical trials. Many clinical trials are designed
to study multiple objectives, such as comparing multiple treatment arms with a con-
trol, or testing multiple primary and secondary endpoints. Many multiple testing
procedures were developed for fixed sample designs to control the familywise error
rate (FWER), i.e., the probability of making one or more false discoveries, or Type I
errors, among all the hypotheses when performing multiple hypothesis tests. Interim
analyses are often conducted for ethical and economical reasons in clinical trials in-
volving human subjects. Group sequential methods are commonly used to control
the Type I error when a single primary hypothesis is tested repeatedly at interim
analyses.
There is less literature for application of multiple testing procedures in group
sequential design. Tang and Geller (1999) showed that if there exists a group sequen-
tial procedure to test every intersection hypothesis at level α then application of the
closure principle of Marcus et al. (1976) leads to a group sequential procedure that
controls the FWER at level α in the strong sense, which means that the FWER con-
trol at level α is guaranteed under any configuration of true and false null hypotheses.
Tamhane et al. (2010) studied the FWER under a hierarchical testing procedure of
one primary and one secondary endpoint with different spending functions for differ-
ent endpoints and various effect sizes and with correlation between endpoints. Hung
et al. (2007) showed that testing a secondary hypothesis at nominal level α after the
66
primary hypothesis is rejected under a group sequential design might not control the
overall Type I error rate in the strong sense.
Marcus et al. (1976) showed that closed testing procedures control the FWER
in the strong sense at level α. Hommel et al. (2007) has shown that many popular
sequentially rejective, weighted Bonferroni-based procedures belong to a subclass of
weighted Bonferroni-based closed test procedures, such as the Bonferroni-Holm pro-
cedure (Holm (1979)), fixed sequence test (Westfall and Krishen (2001)), the fallback
procedure (Wiens (2003)), and Bonferroni-based gatekeeping procedures (Dmitrienko
et al. (2003)); Bretz et al. (2009); Bretz et al. (2011) proposed graphical approaches
to facilitate the visualization and communication of Bonferroni-based closed testing
procedures for common multiple test problems.
Many multiple testing procedures are based on p-values, e.g., the Bonferroni-Holm
procedure (Holm (1979)), the Hochberg procedure (Hochberg (1988)), the Hommel
procedure (Hommel (1988)). The sequential p-value method of Liu and Anderson
(2008a) provides a valid approach to extend these multiple testing procedures into
group sequential designs. Sequential p-values provide valid p-values at interim and
final analyses and when the significance boundary is crossed at any stage. In general,
sequential p-values can be used as inputs to apply any p-value based multiple testing
procedures in group sequential designs.
In this paper, we extend the use of the sequential p-value method of Liu and
Anderson (2008a) in the multiple testing context. We use the graphical approach
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from Bretz et al. (2009) to illustrate how to use sequential p-values for multiplicity
issues in group sequential designs. We also study the operating characteristics of
multiple testing in group sequential designs, e.g., power and expected sample size.
We show that using a group sequential design in multiple hypothesis testing is more
efficient in terms of expected sample size than fixed sample size designs.
4.2 Methodology
4.2.1 The closure principle
Suppose there are m elementary null hypotheses H1, . . . , Hm to be tested. Let
I = {1, . . . ,m} denote the associated index set. Consider all non-empty intersection
hypotheses HJ = ∩j∈JHj, J ⊆ I. For each intersection hypothesis HJ , there exists a
pre-specified local α level test. The closure principle by Marcus et al. (1976) states
that a test procedure rejects any one of these elementary hypotheses, Hi, i ∈ I at
level α, if all intersection hypotheses involving Hi, e.g., HJ with i ∈ J ⊆ I, can be
rejected by corresponding local level α tests. By construction, a closed test procedure
controls the familywise error rate for all the m elementary hypotheses in the strong
sense at level α ∈ (0, 1). Note that for a given set of m elementary hypotheses, the
closure principle may require testing up to 2m − 1 hypotheses. For example, suppose
there are two elementary hypotheses, H1 and H2. Define the intersection hypothesis
H12 = H1
⋂
H2. The closed test procedure rejects H1 if H1 and H12 are rejected, each
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at level α. The closed test procedure rejects H2 if H2 and H12 are rejected, each at
level α. For this example, the closure principle requires testing 22−1 = 3 hypotheses,
i.e., H1, H2 and H12, to control the FWER for these two hypotheses at level α.
4.2.2 Bonferroni-based closed test procedures
Again, consider the problem of testing m elementary null hypotheses H1, . . . , Hm.
The Bonferroni-based closed test procedures apply weighted Bonferroni tests to each
intersection hypothesis HJ . For each intersection hypothesis HJ with i ∈ J ⊆ I
assume a collection of weights wj(J) such that 0 ≤ wj(J) ≤ 1 and
∑
j∈J wj(J) ≤ 1.
These weights quantify the relative importance of the hypothesis Hj included in the
intersection hypothesis HJ . Let pj be the unadjusted p-value for Hj. Then the p-value
for the intersection hypothesis HJ by a weighted Bonferroni test is defined as
pJ = min{qj(J) : j ∈ J}
where
qj(J) =

min{1, pj/wj(J)} if wj(J) > 0
1 if wj(J) = 0
An intersection hypothesis HJ is rejected if pJ ≤ α. Once the p-values for the
individual hypothesis Hi, i ∈ I and the intersection hypotheses HJ = ∩j∈JHj, J ⊆ I
are obtained, the closed test procedures can control the FWER for the m hypotheses
at level α in the strong sense.
Hommel et al. (2007) introduced a useful subclass of sequentially rejective Bonferroni-
based closed test procedures, which substantially reduce the number of tests of in-
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tersection hypotheses to m steps instead of testing all 2m− 1 intersection hypotheses
as usually required by the closure principle. They described a simple and sufficient
condition when applying weighted Bonferroni tests for each intersection hypothesis
wj(J) ≤ wj(J ′) for all J ′ ⊆ J ⊆ I and j ∈ J ′ (4.2.1)
This monotonicity condition in weights of testing the intersection hypotheses en-
sures consonance, i.e., if an intersection hypothesis HJ is rejected, there is an indi-
vidual hypothesis Hj that can also be rejected as well. This substantially reduces
the number of intersection hypotheses to be tested in m steps instead of 2m − 1
steps. We refer to such a procedure as a “shortcut” procedure. Many popular mul-
tiple test procedures belong to this subclass, such as the Bonferroni-Holm procedure
(Holm (1979)), fixed sequence test (Westfall and Krishen (2001)), the fallback pro-
cedure (Wiens (2003)), and Bonferroni-based gatekeeping procedures (Dmitrienko et
al. (2003)).
4.2.3 Sequentially rejective graphical procedure
Bretz et al. (2009) proposed an iterative graphical approach to facilitate the visual-
ization and communication of Bonferroni-based closed testing procedures for common
multiple testing problems. Figure 4.1 shows an initial graph for two primary hypothe-
ses and two secondary hypotheses. Each vertex (node) represents one elementary
hypothesis. H1 and H2 represent two primary hypotheses. H3 and H4 represent two
secondary hypotheses. Here we have I = 1, 2, 3, 4, weights w1(I) = w2(I) = 0.5 for
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the primary hypotheses and weights w3(I) = w4(I) = 0 for the secondary hypotheses,
which means that no secondary hypothesis can be rejected before a primary hypoth-
esis is rejected. The local significance level is defined as αi = αwi(I) for i ∈ I. In
addition, vertices Hi and Hj are connected through direct edges, where the associated
weight gij indicates the fraction of the local significance level αi that is propagated
to Hj once Hi has been rejected. In this example, the local significance levels for
two primary hypotheses are α1 = α2 = 0.5α and the local significance levels for two
secondary hypotheses are α3 = α4 = 0. In this example, g12 = g13 = 0.5 which means
that half of the local significance level α1 is propagated to H2 and the other half is
propagated to H3 once H1 is rejected. If a hypothesis Hi is rejected, the local signifi-
cance level for the remaining non-rejected hypotheses and the graph will be updated
based on the prespecified rules, e.g., weights wi(I) and gij. Repeat the test until no
further hypothesis can be rejected. Details regarding to the rules to update the graph
and weights can be found in Bretz et al. (2009) and Bretz et al. (2011).
The advantages of this graphical approach include its ability to visualize multiple
testing strategy and ease communication of findings. The Bonferroni-based test leads
to simple, consonant closed tests and shortcut procedures as long as the monotonicity
condition of (3.2.1) is satisfied. Bretz, Maurer and Hommel (2010) provided SAS code
to perform the Bonferroni-based sequentially rejective multiple test procedure. Bretz
et al. (2011) presented the gMCP package in R, which offers a convenient way to
implement these procedures in the graphical user interface (GUI).
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Figure 4.1: Multiple testing strategy for two primary hypotheses H1, H2 and two
secondary hypotheses H3, H4
4.2.4 Our proposal
Tang and Geller (1999) showed that if there exists a group sequential procedure to
test every intersection hypothesis at level α then application of the closure principle
of Marcus et al. (1976) leads to a group sequential procedure that controls the FWER
at level α in the strong sense. This approach can be applied to any closed testing
procedure, including shortcut procedures, such as the Bonferroni-based closed testing
procedure. Many multiple testing procedures are based on p-values. The Bonferroni-
based closed testing procedure from Bretz et al. (2009) also uses p-values as inputs
to update the graphs and weights of multiple testing in a fixed sample design.
Sequential p-values from Liu and Anderson (2008a) provide valid p-values at the
interim and final analyses as long as the sample space is ordered by a class of well-
ordered group sequential boundaries: (a) The final p-value, pτ , adheres to the ITT
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principle that all available data are analyzed; (b) sample paths reaching the same
boundary have identical p-values; and (c) pτ is always significant if the significance
boundary is crossed at any stage. We have discussed how to use sequential p-values
to completely order the sample space of a group sequential design in Chapter 3. In
general, sequential p-values can be used as inputs to apply in any p-value based
multiple testing procedures in group sequential designs.
A combination of approaches from Tang and Geller (1999), Bretz et al. (2009) and
Liu and Anderson (2008a) together will provide a simple approach for controlling the
FWER in a group sequential setting with multiple testing. A possible drawback of
Tang and Geller (1999) is that one could choose to retest the previously rejected
hypotheses when we want the analysis of the total data to be significant. If the
previous conclusion is revoked then the power is reduced. This is not an issue for
sequential p-values, since the property of sequential p-values guarantees that the final
p-value is no larger than the previous sequential p-values. The sequentially rejective
graphical procedures from Bretz et al. (2009) are always consonant and thus shortcut
procedures of length m are obtained. The graphical approach and available software
make it easier to communicate the study design.
We use the Bonferroni-based sequentially rejective graphical procedure from Bretz
et al. (2009) to illustrate how to use sequential p-values for multiplicity issues in group
sequential designs. We combine the approaches from Tang and Geller (1999), Bretz et
al. (2009) and Liu and Anderson (2008a) together and give the following proposition.
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Since sequential p-values can control the error rate for any hypothesis at levels of
interest, the Bretz et al. (2009) result can be applied to it to control the FWER in a
group sequential trial.
Propersition 5. The following procedure preserves strong control of the Type I error:
Step 1. Conduct interim analyses and calculate sequential p-values for each individual
hypothesis, based on the group sequential boundaries or α spending functions that
produce a well-ordered sample space.
Step 2. Apply the sequentially rejective graphical approach from Bretz et al. (2009)
at each interim analysis, get the last updated weights and graph.
Step 3. If any hypothesis is not rejected, continue the trial to the next stage, in which
the sequentially rejective graphical approach of Bretz et al. (2009) is repeated, with
the previously rejected hypotheses automatically rejected without retesting.
Step 4. Reiterate Step 3 until all hypotheses are rejected or the last stage is reached.
4.3 Results
Simulation studies can be designed to study the power and expected sample size of
multiple testing in group sequential designs using the scenarios from Table 1 in Bretz,
Maurer and Hommel (2010). We consider a simple situation of a trial comparing
one low dose and one high dose with placebo with one interim analysis and two
endpoints (one primary and one secondary endpoint as shown in Figure 4.1). We use
exponential spending functions to generate group sequential bounds for all primary
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and secondary endpoints. O’Brien-Fleming-type spending functions are often used
for the primary endpoints because of the consideration in stopping the trial early only
if the results are so convincing that it could be considered as unethical to continue
the trial. Pocock-type spending functions spend α more aggressively in the interim
analysis than O’Brien-Fleming-type spending functions do, thus have lower bounds
at the interim analysis and are easier to reject at the interim analysis than O’Brien-
Fleming-type spending functions. Since one generally requires rejecting a primary
hypothesis prior to rejecting a secondary endpoints, the less stringent Pocock-type
spending functions might be a choice for secondary endpoints if you do not wish
to continue the trial after the primary hypothesis is resolved. So we use O’Brien-
Fleming-type spending functions for primary endpoints, but we study both O’Brien-
Fleming- and Pocock-type spending functions for the secondary endpoints.
We study the expected sample size under three strategies to stop the trial when
using the efficacy bounds only:
Strategy 1 the trial will stop as soon as at least one efficacy boundary for the primary
endpoint in either dosage arm is crossed;
Strategy 2 the trial will stop as soon as efficacy boundaries for the primary endpoint
in both dosage arms are crossed;
Strategy 3 the trial will stop as soon as efficacy boundaries for the primary and
secondary endpoints in both dosage arms are crossed.
We also study the power and expected sample sizes for scenarios with both efficacy
75
and futility bounds:
Strategy 4 the trial will stop as soon as at least one efficacy boundary for the primary
endpoint in either dosage arm is crossed, or futility boundaries for both the primary
endpoints are crossed;
Strategy 5 the trial will stop as soon as efficacy boundaries for the primary endpoint
in both dosage arms are crossed, or futility boundaries for both the primary endpoints
are crossed;
Strategy 6 the trial will stop as soon as efficacy boundaries for the primary and
secondary endpoints in both dosage arms are crossed, or futility boundaries for both
the primary endpoints are crossed.
If at the interim analysis the futility bound for only one primary endpoint is
crossed, and neither the efficacy nor futility bound is crossed for the other primary
endpoint, the trial will continue to the final analysis. In general, group sequential
designs require a larger sample size than a fixed sample design to maintain the same
Type I error rate α and power 1−β (Jennison and Turnbull (2000)). The total sample
size for a group sequential trial is often called the maximum sample size due to the
possibility of stopping at the interim analysis. The ratio of the maximum sample size
of a group sequential design to the sample size of a fixed sample design is termed the
inflation factor of a group sequential design. For a study design with α=0.025, β=0.2
and one interim anlysis, the inflation factor is 1.004 when an O’Brien-Fleming-type
spending function is used for efficacy bound for a one-sided test. The inflation factor
76
is 1.107 when a Pocock-type spending function is used for the efficacy bound, which is
larger than that of an O’Brien-Fleming-type spending function. If both efficacy and
futility bounds are used, the inflation factor is even larger than that using efficacy
bounds alone. For example, when a Hwang-Shih-DeCani spending function with
parameter γ = −2 is used for the futility bound, the inflation factor is 1.037 for an
O’Brien-Fleming-type efficacy bound and 1.138 for a Pocock-type efficacy bound.
4.3.1 O’Brien-Fleming-type spending function for both pri-
mary and secondary endpoints
Table 4.1 shows the simulation results when an O’Brien-Fleming-type spending
function is used for both primary and secondary endpoints. Assume H1, H2 are the
primary hypotheses; H3, H4 are the secondary hypotheses. The design parameters
for this simulation study are α1, α2, g12, g21, where α1, α2 are the local significance
levels for the two primary hypotheses. Let g12, g21 indicate the fraction of the local
significance level αi that is propagated to Hj once Hi has been rejected. Let ρ be
the correlation between between the primary and secondary endpoint for each dose.
Let θ1, θ2, θ3, θ4 specify the treatment effect for each endpoint. We study different
realistic scenarios of ρ, θ1, θ2, θ3, θ4 in this simulation study. Power pi defines
the probability of having at least one hypothesis is rejected and individual power pii
defines the probability of rejecting each individual hypothesis. SS1, SS2, SS3 are
the expected sample sizes under Strategy 1 - 3, respectively, when using the efficacy
77
bounds only. Ful1, Ful2, Ful3 are the expected sample sizes under Strategy 4 - 6,
respectively, when both efficacy and futility bounds are applied.
We compare the power of this multiple testing in a group sequential design with
the results in Table 1 from Bretz, Maurer and Hommel (2010) under the fixed sample
design. We find that our results under a group sequential design are consistent with
the results under the fixed sample design with regard to power. The FWER is kept
below level α = 0.025 under the null for all hypotheses (case 1), i.e., when there are
no treatment effects on both primary and secondary endpoints for either dosage arm.
If both doses are effective for the primary endpoint, the power is 0.90 (cases 7-10).
When only using efficacy boundaries (columns SS1 − SS3), sample size saving
is not obvious under the complete null hypotheses (case 1). Sample size savings
are observed for cases when at least one primary endpoint is under the alternative
hypothesis (cases 2-4), i.e., when the effect on at least one primary endpoint is as
hypothesized. More sample size saving is observed when both primary endpoints are
under the alternative hypotheses (cases 7-10). Significant sample size savings accrue
when the treatment effects for the primary endpoints are larger than the hypothesized
(cases 15-17). There is almost no sample size saving for all scenarios when Strategy
3 is applied (column SS3).
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When futility bounds are used (columns Ful1 − Ful3), sample size savings are
most significant under the complete null hypotheses (case 1) due to the futility stop
at the interim analysis when there are no treatment effects. Similar to the cases when
only using efficacy bounds, the sample size savings are significant when the treatment
effects for primary endpoints are larger than the alternatives (cases 15-17), but the
saving is less than when we use efficacy bounds alone due to the larger maximum
sample size when using futility bounds. When the treatment effect on at least one of
the primary endpoints is at the alternative hypothesis, the sample size saving with
the possibility of stopping for futility is less than the sample size saving with only
efficacy stopping due to the fact that stopping for futility requires crossing of futility
boundaries for both the primary endpoints.
4.3.2 O’Brien-Fleming-type spending function for primary
endpoint and Pocock-type spending function for sec-
ondary endpoint
Table 4.2 shows the simulation results when O’Brien-Fleming-type spending func-
tions are used for primary endpoints and Pocock-type spending functions are used
for secondary endpoints.
The general results are similar to those shown in Table 4.1, but using Pocock-type
spending functions for secondary endpoints results in larger sample sizes, compared
to using O’Brien-Fleming-type spending functions. The inflation in sample size due
80
to using a Pocock-type efficacy spending function for secondary endpoints offsets
some of the sample size savings of the group sequential design due to early stopping.
But there are still sample size savings when the null hypotheses are true for both
primary endpoints when using futility bounds (case 1), or when treatment effects for
both primary endpoints are larger than specified by the alternative hypotheses (case
15-17).
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4.4 Discussion
In this paper, we provide a straightforward method for control of Type I error for
multiple hypotheses in a group sequential setting. We propose using the sequential
p-value method of Liu and Anderson (2008a) in the multiple testing context. Sequen-
tial p-values from Liu and Anderson (2008a) provide valid p-values at the interim
and final analyses as long as the sample space is ordered by a class of well-ordered
group sequential boundaries. Tang and Geller (1999) showed that if there exists
a group sequential procedure to test every intersection hypothesis at level α, then
application of the closure principle of Marcus et al. (1976) leads to a group sequen-
tial procedure that controls the FWER at level α in the strong sense. Tang and
Geller’s (1999) proposition can be extended to any closed testing procedures, includ-
ing the Bonferroni-based sequentially rejective graphical procedure from Bretz et al.
(2009). In general, sequential p-values can be used as inputs in any p-value based
multiple testing procedures in group sequential designs. Our proposal combines these
approaches and uses sequential p-values at interim and final analyses for each indi-
vidual hypothesis as inputs for the p-value based closed test procedures for multiple
testing in group sequential designs. Liu and Anderson (2008b) suggested sequential
p-values for multiple testing (e.g., hieratical endpoints, sequential Hochberg test, se-
quential adaptive closed testing procedure). We have extended this here to apply to
p-value based closed test procedures and orderings based on spending functions, the
most common form of designing group sequential trials.
83
We study the operating characteristics of multiple hypothesis testing in group
sequential designs, e.g., power and expected sample size. Simulations confirm that
our proposal controls the FWER at level α in the strong sense. Simulations also show
that using a group sequential design in multiple hypothesis testing is more efficient
in terms of expected sample size than fixed sample size designs when treatments
are efficacious, or when there are no treatment effects at all if futility bounds are
applied. We also compare different spending functions for secondary endpoints. We
notice that using Pocock-type spending functions for secondary endpoints results in
larger sample size compared to using O’Brien-Fleming-type spending functions for
secondary endpoints, thus the sample size saving is somewhat diminished when a
Pocock-type spending function is used for secondary endpoints. This is due to the
fact that the spending functions for the primary endpoints in both examples are an
O’Brien-Fleming-type spending function and the strategies to stop the trial require
rejection of at least one primary endpoint. This contrasts to the case of a single
endpoint where often Pocock-type bounds will result in a smaller expected sample
size. We also notice that sample size savings for Strategy 2 and Strategy 3 (or
Strategy 4 and Strategy 5) are much less than that for Strategy 1 (or Strategy
6). This is expected, because it is harder to reject two or more hypotheses than to
reject just one hypothesis. In reality, a trial in which the null hypothesis is rejected
for at least one dose level could represent a success.
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Chapter 5
Conclusion
We have developed solutions to applied problems that may be widely used. We
propose a stepwise adaptive design to lessen the information on treatment effect re-
vealed at interim analysis. For a two stage design, we use a step function for the
second-stage sample size adaptation. The stepwise adaptive design is a pre-specified
design and optimized through minimizing expected sample size among a class of these
designs. For a prior distribution of treatment effect θ ∼ N(δ/2, (δ/2)2), the stepwise
adaptive design has an inverted “U” shape with two choices of second-stage sam-
ple size: the total sample size is close to the fixed design sample size when the test
statistic at interim analysis is close to the futility bound or efficacy bound; the total
sample size increases about 20% compared to the fixed design sample size when the
test statistic at interim analysis is intermediate. The stepwise adaptive design is sim-
plified compared to the fully optimized two-stage adaptive design, which also reveals
one or two exact treatment effects at interim analysis due to its continuous nature.
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Compared to the optimal two-stage group sequential design which has one choice for
second-stage sample size, the stepwise adaptive design is less likely to require the
maximum sample size and the minimum second-stage sample size is much smaller. In
general, the stepwise adaptive design has similar expected sample size, overall power,
and predictive power compared to the fully optimized two-stage adaptive design and
optimal two-stage group sequential design. The shape of the optimal stepwise adap-
tive design changes appropriately under different prior distributions for the parameter
of interest. Compared to the adaptive design based on promising conditional power,
which might require doubling the sample size, the optimized stepwise adaptive de-
sign often has higher power and smaller expected sample size and requires a larger
observed treatment effect at the rejection boundary (the observed treatment effect
for the adaptive design based on promising conditional power might be too small to
be clinical meaningful).
In group sequential designs, the spending function approach has become common
because of its flexibility in accommodating unequally-spaced analyses and allowing
some leeway in moving, adding or deleting interim analyses as long as this is done
without knowledge of treatment effects. Many choices of spending functions also pro-
vide flexibility in choosing a unique shape of efficacy or futility boundaries to satisfy
a particular clinical trial design. However, many popular spending functions can not
completely order the sample space for a group sequential design, though they can
form well-ordered sample spaces. We define “well ordered sample space” and “com-
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pletely ordered sample space”, and give sufficient conditions to define a well ordered
sample space for a spending function. Maurer and Bretz (2013) provides similar
conditions for well ordered sample space, though they call it well ordered families
of spending functions and define that through the nominal significance levels at the
interim analyses rather than the corresponding boundary value. We have proposed a
simple method to transform a spending function to one that can completely order a
group sequential design sample space. We also have shown that exponential spending
function can completely order a sample space and also provide flexibility in different
shape of design boundaries. We show examples in which both the transformed spend-
ing function and exponential spending functions provide completely ordered sample
space. We extend the sequential p-value ordering to test the alternative hypothesis.
The two one-sided sequential p-values against the null or alternative hypothesis may
provide useful information for the Data Monitoring Committee.
Many multiple testing procedures are available for fixed sample designs. Many of
these procedures require p-values of testing single or intersection hypotheses. The se-
quential p-value method provides valid p-values at interim and final analyses. In gen-
eral, sequential p-values can be used as inputs to apply in any p-value based multiple
testing procedures in group sequential designs. We propose combining the sequential
p-value method and p-value based closed test procedures, e.g., sequentially rejective
graphical procedure, to control the familywise error rate for a group sequential design
with multiple testing. Liu and Anderson (2008b) suggested sequential p-values for
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multiple testing issues. We have extended this here to apply to p-value based closed
test procedures and orderings based on spending functions, the most common form
of designing group sequential trials. Our simulation studies showed that this method
controls familywise error rate at a level comparable to that of a fixed sample design,
and using a group sequential design in multiple hypothesis testing is more efficient
than fixed sample size designs in many scenarios.
The findings described suggest promising avenues for future research. An appro-
priate future research pursuit would be to make these and related procedures readily
available for use through software. It is of interest to find a general set of conditions
under which a family of spending functions completely order a sample space. The
sequential p-value method and spending functions, which can completely order the
sample space of a group sequential design, also provide a way to form confidence
intervals. For a group sequential trial with both efficacy and futility boundaries, dif-
ferent spending functions can be chosen for Type I or Type II error spending. It
would be of interest to form asymmetric one-sided confidence intervals for each sam-
ple space orderings by Type I error or Type II error. This asymmetric confidence
interval would provide valuable information for testing both the null and alternative
hypotheses. We have discussed several strategies on stopping for trials with multiple
endpoints. Further guidance on this topic may be of interest.
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